ERBB2 and breast carcinoma: Given that patients with HER2-positive, HR-positive breast cancer are less likely to respond to standard combination of anti-HER2 and chemotherapy (5–8), several studies have valuated the possibility of combined treatment with anti-HER2 and endocrine therapy.